Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 16/20 | 0.48 |
| ▸ | CTPS2 | Q9NRF8 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22490778 | 0.85 | CTPS1 (0.48) | CTPS1CTPS2 | |
| SCHEMBL22490817 | 0.83 | SMN1; SMN2 (0.60) | CTPS1SMN1; SMN2 | |
| SCHEMBL22490773 | 0.83 | CTPS1 (0.50) | CTPS1CTPS2HDAC3HDAC4HDAC1 | |
| SCHEMBL21044438 | 0.81 | SMN1; SMN2 (0.49) | CTPS1CTPS2SMN1; SMN2 | |
| SCHEMBL21044261 | 0.81 | CTPS1 (0.48) | CTPS1CTPS2HDAC3HDAC4HDAC1 | |
| SCHEMBL22490819 | 0.77 | CTPS1 (0.45) | CTPS1CTPS2SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL21044216 | 0.77 | CTPS1 (0.46) | CTPS1CTPS2 | |
| SCHEMBL32663042 | 0.76 | CTPS1 (0.44) | CTPS1CTPS2 | |
| SCHEMBL24088705 | 0.76 | CTPS1 (0.43) | CTPS1CTPS2 | |
| SCHEMBL24088635 | 0.75 | CTPS1 (0.42) | CTPS1CTPS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717465-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20250263407-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-08-21 | — | — | US | disclosed |
| US-12319680-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-06-03 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-11505547-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2022-11-22 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3717465-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885CTPS2 2833/4885SMN1; SMN2 2367/4885 |
| US-12319680-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885CTPS2 2833/4885SMN1; SMN2 2367/4885 |
| US-20250263407-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885CTPS2 2637/4885SMN1; SMN2 1991/4885 |
| US-11505547-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885CTPS2 2833/4885SMN1; SMN2 2367/4885 |
| US-20210380575-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885CTPS2 2833/4885SMN1; SMN2 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.